Susvimo (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor for patients with neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Susvimo was first approved for neovascular (wet) age-related macular degeneration in October 2021. Ranibizumab was first approved in June 2006 for the treatment of neovascular (wet) age-related macular degeneration.
Medication Overview:
- Brand Name: Susvimo
- Generic Name: ranibizumab
- Treatment for: Neovascular age-related macular degeneration, diabetic macular edema, and diabetic retinopathy
- Manufacturer(s): Genentech
- Initial FDA Approval: October 2021
| Indicated Condition | Indication | Age | Date Approved |
|---|---|---|---|
| Wet Age-related Macular Degeneration | Indicated for the treatement of patients with neovascular (wet) age-related macular degeneration who have previously responded to at least two intravitreal injections of a VEGF inhibitor. | N/A | October 2021 |
| Diabetic Macular Edema | Indicated for the treatment of patients with diabetic macular edema who have previously responded to at least two intravitreal injections of a VEGF inhibitor. | N/A | February 2025 |
| Diabetic Retinopathy | Indicated for the treatment of patients with diabetic retinopathy who have previously responded to at least two intravitreal injections of a VEGF inhibitor. | N/A | May 2025 |
Warnings and Precautions:
The SUSVIMO implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septu dislodgement, vitreous hemorrhage, conjunctival retraction, conjunctival erosion, and conjunctival bleb. Patients should be instructed to report signs or symptoms that could be associated with these events without delay. Additional surgical and/or medical management may be required.
Vitreous Hemorrhage: Temporarily discontinue antithrombotic medication prior to the implant insertion procedure to reduce the risk of vitreous hemorrhage. Vitrectomy may be needed.
Postoperative Decrease in Visual Acuity: A decrease in visual acuity usually occurs over the first two postoperative months.
Dosage and Administration:
For intravitreal use via Susvimo ocular implant.
Neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME): The recommended dose of Susvimo (ranibizumab injection) is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the Susvimo implant with refills every 24 weeks (approximately six months).
Diabetic retinopathy (DR): The recommended dose of Susvimo (ranibizumab injection) is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the Susvimo implant with refills every 36 weeks (approximately nine months).
Supplemental treatment with 0.5 mg intravitreal ranibizumab injection may be administered in the affected eye if clinically necessary.
Perform the initial implantation, refill-exchange, and implant removal (if necessary) procedures under strict aseptic conditions.
Contraindications:
Ocular or periocular infections.
Active intraocular inflammation.
Hypersensitivity.
Adverse Reactions:
The most common adverse reactions (≥ 10%) were conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, conjunctival disorder, cataract and vitreous hemorrhage.
Examples of Ranibizumab in Guidelines
Age-Related Macular Degeneration
- American Academy of Ophthalmology, April 2025
- “The Archway phase 3 study showed that patients receiving the ranibizumab implant had VA gains equivalent to patients receiving monthly ranibizumab injections.”
- American Academy of Ophthalmology, April 2025
- “The study concluded that ranibizumab rapidly and sustainably improved vision, reduced the risk of further vision loss, and improved macular edema in patients with DME, with low rates of ocular and nonocular side effects.”
Diabetic Retinopathy: Management and Monitoring
- National Institute for Health and Care Excellence, August 2024
- “In August 2024, NICE technology appraisal guidance recommended ranibizumab, brolucizumab, faricimab and aflibercept as options for treating visual impairment in eyes with central retinal thickness of 400 micrometres or more.”
Please note: This article is current as of January 22, 2026. Consult our clinical guidelines library or drug information tool to ensure you always have the most up-to-date information.
Sign up for alerts to keep up with the latest clinical guidelines and guideline updates.
Copyright © 2026 Guideline Central, all rights reserved.